Could an HIV drug protect the aging brain?

NCT ID NCT06519357

Ongoing Disease control Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether lamivudine, an antiviral drug used for HIV, can lower levels of brain-damage-related proteins in the blood of people with mild cognitive impairment (MCI) who also have early signs of Alzheimer's disease. Twenty-three participants will take lamivudine daily for 24 weeks. Researchers will measure changes in biomarkers and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lamivudine (an antiviral drug used for HIV and hepatitis B)
What this could lead to: If it works, this could point toward a new way to slow or prevent Alzheimer's disease by reducing brain inflammation.
What could go wrong: This is a very small, early pilot study with only 23 people. It tests blood markers, not memory or thinking skills, so even if markers improve, it may not help patients feel better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MILD COGNITIVE IMPAIRMENT

Contacts and locations

Show contact details

Locations

Germans Trias I Pujol Hospital

Badalona, BARCELONA, 08916, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.